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Abstract
An intermediate response measure that accurately predicts efficacy in a new setting can
reduce trial cost and time to product licensure. In this paper, we define a trial level general
surrogate as a trial level intermediate response that accurately predicts trial level clinical re-
sponses. Methods for evaluating trial level general surrogates have been developed previously.
Many methods in the literature use trial level intermediate responses for prediction. However,
all existing methods focus on surrogate evaluation and prediction in new settings, rather than
comparison of candidate trial level surrogates, and few formalize the use of cross validation
to quantify the expected prediction error. Our proposed method uses Bayesian non-parametric
modeling and cross-validation to estimate the absolute prediction error for use in evaluating and
comparing candidate trial level general surrogates. Simulations show that our method performs
well across a variety of scenarios. We use our method to evaluate and to compare candidate
trial level general surrogates in several multi-national trials of a pentavalent rotavirus vaccine.
We identify two immune measures that have potential value as trial level general surrogates and
use the measures to predict efficacy in a trial with no clinical outcomes measured.
Bayesian non-parametrics; Cross-Validation; Meta-analysis; Surrogate markers; Vaccines
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1 Introduction
Many different definitions of a surrogate exist. The most common definition is an intermediate
response measurement that accurately predicts the clinical endpoint of interest. This definition lacks
some necessary details about what ‘accurately predicts’ means and in what setting this prediction
is done, but it is a useful starting point. Gilbert et al. [2008] refined the concept of a surrogate in
the vaccine trial setting, proposing three levels: correlates, specific surrogates of protection, and
general surrogates of protection. A correlate is a biomarker that is associated with the outcome
in the vaccine arm or over both arms and a specific surrogate of protection, is a biomarker that is
associated with efficacy. The definition of a general surrogate of protection is most closely related
to the common definition of a surrogate: a biomarker on which the treatment effect can be used
to accurately predict the treatment effect on the clinical outcome in a new setting. These levels
are informative for general clinical trials as well. To make clear that we are considering the more
general clinical trial setting, we will call biomarkers that are predictive of the clinical treatment
effect in a new setting general surrogates (GS). Numerous papers have investigated the evaluation
of biomarkers as GS, including Daniels and Hughes [1997], Gail et al. [2000], Burzykowski et al.
[2001], Dai and Hughes [2012].
The definition of a GS in Gilbert et al. [2008] does not define in what new trial settings the GS
will be useful or if the surrogate is at the individual or trial level. An individual level surrogate is
a measurement the treatment effect on which is predictive of the clinical effect at the individual
level. The effect of treatment on a trial level surrogate can be used to infer what the trial results
would have been had the clinical outcome been measured. A GS can be predictive at the trial level
or the individual level, or both. As is outlined in Korn et al. [2005], these two types of surrogacy
do not imply each other and can be unrelated. Most of the literature focuses on the evaluation of a
potential trial level general surrogate in studies in which both the GS and the clinical outcome are
measured, yet little attention is given to what information is available to support the generalizability
of the association of the surrogate and the clinical endpoint to a new setting. All existing general
surrogate evaluation methods, to our knowledge, only consider summary measures for surrogate
evaluation rather than comparison of candidate GS, and most are based on within sample prediction
intervals. Only Baker [2006] attempts to formalize the exogenous quantification of the expected
error when predicting in a new setting, using a similar summary of prediction error to our suggested
method for a binary surrogate. In addition, most existing methods are specific for the type of data
collected and require strict modeling assumptions. Dai and Hughes [2012] propose a general method
for evaluating a trial level GS, but they require individual level data be available in all trials and
suggest a within sample evaluation of prediction error based on a linear relationship between the
treatment effects.
In this paper, we provide a precise definition of a trial level general surrogate. We propose a
general and flexible evaluation and prediction method that differs from existing meta-analytic eval-
uation methods in several ways. Our suggested estimation method can be used on individual level
or trial level data, similar to Daniels and Hughes [1997] (DH). It allows for a flexible association
between the treatment effect on the trial level general surrogate and the treatment effect on the
clinical outcome and a flexible distribution for both true treatment effects over the trials. Our pro-
posed evaluation method uses a Bayesian cross-validation approach to quantify the prediction error
when estimating the treatment effect in a new setting. We propose the use of absolute prediction
error, similar to that of Tian et al. [2007] as a summary error for evaluation and comparison of
candidate trial level general surrogate. The absolute prediction error is easily interpretable because
it is on the scale of the treatment effect on the clinical outcome. We also outline a suggested
nomenclature for classifying support for the generalizability of an evaluated trial level general sur-
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rogate. We build on the work of Daniels and Hughes [1997], taking a Bayesian approach to trial
level general surrogate evaluation while allowing for the within trial estimation approach of Dai
and Hughes [2012] when individual level data are available. Software implementing our method in
R and JAGS is available in the supplementary materials.
We use our method to evaluate and compare trial level general surrogates for the pentavalent
rotavirus vaccine RotaTeqTM(RV5) (Merck & Co. Inc., Kenilworth, New Jersey). RV5 has been
shown to be efficacious against rotavirus gastroenteritis in many settings, but in developing countries
where the disease burden is highest, this efficacy is lower than in developed nations. A universal
and clear measure of post-randomization immune response that explains the efficacy differences
among the trials and that could potentially accurately predict efficacy in future settings has yet to
be clearly identified. We use our approach to attempt to identify trial level general surrogates in
the setting of the RV5 trials.
In Section 2 we outline our proposed methods for estimation, prediction, evaluation and com-
parison. In Section 3 we explore the operating characteristics of our methods in several settings,
one of which follows closely the setting of the RV5 trials. In Section 4 we outline our suggested
nomenclature for the generalizability of a TLGS. In Section 5 we use our method to investigate
TLGS of rotavirus gastroenteritis of any severity in the RV5 trials, and in Section 6 we summarize
our findings and suggest possible extensions to the proposed methods.
2 Methods
We refine the definition of a GS from Gilbert et al. [2008] to indicate whether the prediction is at
the individual or trial level and the characteristics of the new setting where such a GS might be
used. If the trial level treatment effect on a biomarker can be used to predict (with low prediction
error) a trial level clinical treatment effect and this predictive association is generalizable to a new
setting, then the biomarker is a trial level general surrogate (TLGS) for that clinical outcome in
that new setting.
This definition clearly states that the surrogate is at the trial level and indicates the settings
where the TLGS can be used.
To outline our proposed methods for evaluation and comparison of biomarkers as TLGS, we
first define some notation. For subject i ∈ {1, . . . , Nj} in trial j ∈ {1, . . . , J}, let Zi,j = {0, 1}
be the treatment indicator, Yi,j the clinical endpoint (the same over all trials) and Ai,j,k the kth
biomarker measure, k ∈ {1, . . . ,K}. At the trial level, let T1,j,k be the true treatment effect on
the kth biomarker measurement and let T2,j be the true treatment effect on the clinical outcome.
Let Nj,k and Nj,2 be the set of subjects with the kth candidate TLGS and the clinical outcome
measured in trial j, respectively.
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2.1 Within Trial Models
2.1.1 Models for Subject Level Data
When subject level data are available in one or more trials, we specify the following linear models
for the (transformed) mean, median, or hazard for the candidate TLGS and the clinical outcomes,
h1,k(F [Ai,j,k|Zi,j ]) = ζ0j,k + T1,j,kZi,j , (1)
h2(F [Yi,j |Zi,j ]) = γ0j + T2,jZi,j , (2)
where ζ0j,k and γ0j denote the jth trial specific intercepts for the kth biomarker measurement
and the clinical outcome, respectively. Models (1) and (2) are specified in terms of the distribution
function, F (.), of A and Y and can be any set of models from which asymptotically normal coefficient
estimates are obtained, including generalized linear models and survival models. We fit the models
separately for each trial and response (outcome or biomarker). For this reason, Nj,k and Nj2, the
subjects in each trial used to fit (1) and (2) respectively, do not need to have both the outcome
and biomarkers provided the (implicit) missingness is random and/or by design. We denote the
estimates of the treatment effects as T̂1,j,k and T̂2,j with standard errors, σˆ1,j,k and σˆ2,j , j ∈
{1, . . . , J}.
Let OJ,k be the vector of estimated treatment effects and estimated standard errors over all
J trials for the kth candidate GS; OJ,k = (T̂1,1,k . . . T̂1,j,k, T̂2,1 . . . T̂2,J , σ̂1,1,k . . . σ̂1,j,k, σ̂2,1 . . . σ̂2,J)
and define OJ to be the vector of all estimated treatment effects and standard errors over all K
candidate GS and clinical outcome data in a given set of J trials. We will call OJ the vector of
observed ’data’. Also define T2 = (T2,1 . . . T2,J) and T1,k = (T1,1,k . . . T1,J,k).
Dai and Hughes [2012] use an estimating equation approach to estimate the joint sampling
distribution of the estimated treatment effects from (1) and (2). Using their approach the correlation
between the estimated treatment effects can be estimated. However, an estimate of this covariance is
not required to evaluate the candidate TLGS ([Daniels and Hughes, 1997]), and complex missingness
by design can make this covariance estimation complex.
2.1.2 Approximate Likelihood
We assume that the estimated treatment effects are consistent and asymptotically normal and can
be well approximated by
T̂1,j,k ≈ N(T1,j,k, σˆ21,j,k) and T̂2,j ≈ N(T2,j , σˆ22,j).
Note that the estimated treatment effects can be obtained by fitting models (1) and (2) or from
the literature. We denote these models for the estimated treatment effects given the true treatment
effects by f1jk(T̂1,j,k|T1,j,k, σˆ1,j,k) and f2,j(T̂2,j |T2,j , σˆ2,j). The joint distribution of the estimated
treatment effects is given by
fj,k(T̂1,j,k, T̂2,j |T1,j,k, T2,j , σˆ1,j,k, σˆ2,j) = f1jk(T̂1,j,k|T1,j,k, σˆ1,j,k)× f2,j(T̂2,j |T2,j , σˆ2,j), (3)
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where we assume independence conditional on the true treatment effects. Based on these (ap-
proximate) trial specific models, the likelihood over all the trials for the kth TLGS is given by∏J
j=1 fj,k(T̂1,j,k, T̂2,j |σˆ1,j,k, σˆ2,j , T2,j , T1,j,k), as the estimates between trials are assumed to be inde-
pendent. In what follows, the estimated standard errors σˆ1,j,k and σˆ2j,k will be treated as fixed.
When the individual level data is available, we can estimate the covariance of (T̂1,j,k, T̂2,j), and
replace the two independent normals with a bivariate normal. One could also use the individual
data directly by using models (1) and (2) to form the likelihood. However, such a formulation is
unlikely to substantially improve evaluation of GS at the trial level as was demonstrated in Korn
et al. [2005]. Therefore, we focus on a two step approach: first, estimating the treatment effects
within each of a set of trials, and second, constructing an approximate likelihood based on those
estimates.
2.2 Between Trial Model and Priors
We specify a non-parametric prior for the distribution of the true treatment effect on the candidate
GS, T1,j,k. In particular we propose a Dirichlet process mixture of normals [MacEachern and Mu¨ller,
1998],
T1,j,k ∼ N(µ1,j,k, τ1,j,k) (4)
(µ1,j,k, τ1,j,k) ∼ G
G ∼ DP (ω,G0)
For ω, we specify a U(1, J) prior. We use this prior both to bound ω away from zero and to
allow for clustering in the true trial level biomarker effects, T1,j,k. We specify the base measure
G0 to be the product of a normal and a gamma distribution where each µ1,j,k follows a normal
distribution with mean ϕ1,k and variance σ
2
µ1,k
and each 1/τ1,j,k follows a gamma distribution with
parameters (ψ1,k, ξ1,k). Denote the vectors of trial level parameters as µ1k = (µ1,1,k, . . . , µ1,J,k)
and τ1k = (τ1,1,k, . . . , τ1,J,k). We use data-dependent hyper-priors for the parameters in the base
measure as recommended in Taddy [2008].
We now specify a flexible model for the true trial level clinical treatment effect given the true
trial level treatment effect on the TLGS, [T2,j |T1,j,k]. Specifically, T2,j = m(T1,j,k, βk, bk) + j,k,
where j,k are independent N(0, σ
2
 ). The function m(T1,j,k, βk, bk) is defined as:
m(T1,j,k, βk, bk) = β0,k + β1,kT1,j,k +
M∑
m=1
bm,k|T1,j,k − rm| (5)
The r1 < r2 < . . . < rM are fixed knots/changepoints. The coefficients associated with each
knot, bm,k are penalized/shrunk using N(0, κ
2
bk
), with κ2bk given an inverse gamma(1, 3) prior as
recommended in Crainiceanu et al. [2005]. The parameters β0,k and β1,k are given independent
N(0, σ2βk) priors, with 1/σ
2
βk
set to 1e−6. We use a diffuse inverse-gamma prior for σ2 . The full set
of hyper-parameters will be denoted as ν = {τ 21k,µ1k, ϕ1,k, σ2µ1,k , ψ1,k, ξ1,k,bk, κ2bk , σ2 , β0,k, β1,k,
ω}.
For the evaluation procedure presented in Section 2.3, we also need the null distribution of T2,
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i.e., the distribution of the T2 independent of T1. We do not use the marginal T2 derived from
the above models to avoid any potential model misspecification for the model for T2|T1. Instead,
we specify the (null) prior for the true clinical treatment effects T2 ignoring all candidate TLGS
information using the same specification and priors as in (5).
To compare candidate trial level surrogates, more than one candidate will need to be available
in a given set of completed trials. When K candidates are available, we use an additive model for
[T2,j |T1,j,k, . . . T1,j,K ], T2,j =
∑
kmk(T1,j,k, βk, bk) + j , where m has the form as (5). The model
containing all information from all K candidates is called the full model.
2.3 Evaluation and Comparison
Our objective is to predict the true clinical treatment effect in a new setting J + 1 where the
estimated treatment effect on the clinical outcome, T̂2,J+1, is not observed. For this prediction we
use the posterior distribution of T2,J+1, the true treatment effect on the clinical outcome in the
new trial J + 1, given the observed data, which includes T̂1J+1,k and σˆ1J+1,k in addition to OJ,k,
i.e., T2,J+1|OJ,k, T̂1,J+1,k, σ̂1,J+1,k. As we are interested in comparing and evaluating candidate
TLGS based on their predictive power, we need to determine the quality of the predictions from
this distribution.
To evaluate predictive accuracy and compare candidate TLGS, we will use the expected absolute
prediction error,
DJ+1,k = E|T2,J+1 − T̂ ∗2,J+1|, (6)
where T̂ ∗2,J+1 is our point prediction of the treatment effect on the outcome in the new setting (trial
J + 1). The summary DJ+1,k is the expected absolute prediction error for a new trial setting J + 1.
The merits and properties of the expected absolute prediction error were outlined in Tian et al.
[2007] for independent and identically distributed data where the true outcome, T2, was observed.
In our setting, the T2 are unlikely to be identically distributed, although we assume that they are
independent, and they are never observed. To estimate DJ+1,k, we could estimate the error we
make for each observed trial j by comparing a leave-one-out estimate, T̂ ∗2,j to the true T2,j value,
d̂j,k, and then average over the J trials,
D̂J+1,k = (1/J)
∑
j
d̂j,k = (1/J)
∑
j
|T2,j − T̂ ∗2,j |. (7)
A cross-validated estimate of this nature was found to have good finite sample size properties for
iid data in Tian et al. [2007]. Recall though, that we do not observe the true T2,j , so we cannot
directly use (7) either.
Our leave one out prediction of T2,j , T̂
?
2,j , is computed from the posterior obtained by excluding
T̂2,j and σ̂2,j as well as all information about all other candidate GS, from the data,
T̂ ?2,j = E[T2,j |OJ(−j),k, T̂1,j,k, σ̂1,j,k],
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where OJ(−j),k is all information about the clinical outcome and the kth candidate GS in all
{1, . . . , J} trials less trial j. Since we do not observe the true T2,j , even in the evaluation trials, we
will use an approximation to the distribution of the absolute prediction error to assess the TLGS.
In particular, we use
d˜j,k|OJ ∼ |T2,j − Tˆ ?2,j |, (8)
the posterior distribution of the approximate absolute prediction error for trial j using all the data,
OJ. Here Tˆ
?
2,j = E[T2,j |OJ(−j),k, T̂1,j,k, σ̂1,j,k]|. By taking the expected value of (8), i.e., with respect
to the posterior distribution, T2,j |OJ, we obtain an approximation of d̂j,k in (7). For evaluation of
a TLGS in an arbitrary new setting, we use the mixture distribution, D˜J+1,k ∼ (1/J)
∑
j d˜j,k. The
expectation of D˜J+1,k is an approximation of (7) and is a single value comparison for candidate
TLGS in a new setting.
The distribution of D˜J+1,k is the distribution of interest for comparing candidate TLGS and
as D˜J+1,k is on the scale of the true clinical effect, a first step in TLGS evaluation can be a
comparison of D˜J+1,k to the smallest clinically relevant effect, as was suggested in Baker [2006].
However, to evaluate the absolute quality of a candidate TLGS we will compare D˜J+1,k to the
absolute prediction error in the absence of T̂2,j or T̂1,j,k; we will denote this as D̂J+1,0. We use the
null model prior for the distribution of the true T2,j introduced at the end of Section 2.2. Similar to
the development for d̂j,k, we use the following approximate distribution of the absolute prediction
error,
d˜j,0|OJ ∼ |T2,j − E[T2,j |OJ(−j,−1)]|, (9)
whereOJ(−j,−1) denotes the observed clinical outcome information less that in trial j, i.e., OJ(−j,−1) =
(T̂2,q, σ̂2,q) : q ∈ {1, . . . , j − 1, j + 1, . . . , J}}. The distribution D˜J+1,0 ∼ (1/J)
∑
j d˜j,0. D˜J+1,0 is a
good baseline for candidate TLGS evaluation because it quantifies the amount of error that occurs
when no potential TLGS are used in the model.
To evaluate and to compare candidate GS based on D˜J+1,k and D˜J+1,0 , a joint graphical
representation of the density estimates can be useful. Densities of D˜J+1,k that have more mass
at 0 with shorter tails are evidence of superior candidates, as this implies greater probability of
lower prediction error. Figure 1 is an illustration of how the density plots can be used to compare
and to evaluate candidate trial level general surrogates. Both candidate TLGS in Figure 1 are
superior to the null, D˜J+1,0, while the density of D˜J+1,l in comparison to that of D˜J+1,k suggests
that candidate l is superior to candidate k; in this example, candidate l is an ideal TLGS, with a
true D̂J+1,l = 0, from using the true T2,j as the estimated treatment effect on the candidate GS.
However, the kth candidate is still a very useful TLGS.
The probability P (D˜J+1,0 < D˜J+1,k), can be used to quantify the strength of evidence that a
given candidate TLGS has any value. Small probabilities suggest that there is evidence that the
kth candidate has value as a TLGS to aid in the prediction of the clinical treatment effect in a
new trial setting. One can also rank candidates using the set of point and interval estimates from
the set of {D˜J+1,1, . . . , D˜J+1,K} distributions. The probability P (D˜J+1,k < D˜J+1,l), can be used
to quantify the strength of evidence for the superiority of a given candidate over another within
the same set of evaluation trials. Here, small probabilities suggest that there is evidence of the
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Figure 1: Density estimates for D˜J+1,k, D˜J+1,l and D˜J+1,0. Candidate TLGS k is a good, but not
perfect GS. Candidate l is an ideal TLGS, with a true D̂J+1,l = 0. D˜J+1,0 corresponds to the
model containing no candidate GS. Large mass closer to 0, and less spread away from zero, for
D˜J+1,k and D˜J+1,l, suggests a smaller mean and lower variance of the approximate distribution of
the absolute prediction error.
superiority of the lth TLGS candidate over the kth candidate, while large probabilities provide
evidence of the opposite.
2.4 Posterior computation
Computation of all quantities of interest requires four steps, which we outline below.
1. Sample from the posterior of the full model using all observed data to obtain the marginal
posterior of each T2,j in JAGS. This step provides the best estimate of the ’true’ value of the
treatment effect on the clinical outcome.
2. Removing the observed clinical data information for trial j, we sample from the corresponding
posterior in JAGS to obtain the leave-the-jth-trial-out-estimate, T ∗2,j . We repeat for all J
evaluation trials.
3. Using only the clinical information from the other trials besides trial j and removing all
candidate surrogate information, we sample from the corresponding posterior to obtain an
estimate of the true treatment effect on the clinical outcome, the marginal or null leave-the-
jth-trial-out-estimate. We repeat this for all J evaluation trials.
4. We use the posteriors of T2 from steps 1 and 2 to obtain the distribution of D˜J+1,k and the
posterior distributions of T2 from steps 1 and 3 to obtain the distribution D˜J+1,0.
We use the posterior from step 2 to estimate the true clinical treatment effect in a trial setting
where only the candidate surrogate is measured.
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3 Simulations
We investigate the performance of our method in several scenarios, including for different rela-
tionships between the true treatment effect on the clinical outcome, T2,j , and the true treatment
effect on the surrogate, T1,j,k and for different distributions governing the true T1,j,k, including a
single normal or a mixture of normals. For each of these scenarios we investigate the impact of the
magnitude of the errors with which the treatment effects were estimated within the trials, σˆ1,j,k
and σˆ2,j . For the scenarios where T1,j,k are generated from a normal distribution, we fix the mean
and standard deviation (SD) of each T1,j to be 2 and 1, respectively. In the mixture of normals
settings, we generate T1,j,k from an equally weighted mixture of 3 normals with means (−1, 0, 2)
and SDs of 1. We fix the SD of the generated T2,j , conditional on Tj,1,k, to be 1.
For each scenario we simulate 200 datasets of 20 trials, unless otherwise specified. The exact
specifications of the simulation scenarios are given in Appendix A of the supplementary materi-
als; the R and JAGS code used to generate the data and fit the models is also available in the
supplementary materials. The last scenario in each table is based on the rotavirus vaccine trial
application, with 12 trials and using the set of T̂1 and σ̂1 from one of the candidate GS as well as
assuming a strong linear association between the true treatment effects. For our method outlined
in Section 2, we use a piecewise linear model as given in (5) with knots at the 33rd and 66th
percentiles of the T̂2, for the prior on T2,j |T1,j,k. We compare our method’s predictive accuracy, as
described in Section 2.4, with: 1) a linear regression on the estimated treatment effects (referred to
as ’linear model’ in the tables) and 2) the method of Daniels and Hughes [1997] (referred to as DH
in the tables).
Table 1 reports the mean and SD of D̂J+1,k = (1/J)
∑
j |T true2,j − E[T2,j |OJ(−j), T̂1,j,k, σ̂1,j,k]|.
T true2,j is the true clinical treatment effect for trial j and J is the number of trials. Table 1 also
displays the mean and bias of the posterior mean of D˜J+1,k, given in (8), in comparison to D̂J+1,k.
Both the DH method and our proposed method estimate D̂J+1,k more accurately than the linear
model in all scenarios. The DH method and our proposed method have similar bias, both well
below Monte Carlo error; this suggests relative unbiasedness for both methods. The D̂J+1,k are
always lower for our proposed method in non-linear scenarios and similar in linear scenarios.
Table 2 reports the average P (D˜J+1,0 < D˜J+1,k) over the 200 simulated datasets for each sce-
nario and method. The averages are near 1/2 for both the DH method and our proposed method
in the first row of Table 2, the scenario where there is no useful candidate surrogate. In addition,
the lower probabilities in all other scenarios suggest that this probability can help quantify the
value of a candidate as a TLGS. The low probabilities for all scenarios for the linear model are
caused by the biased estimation of DJ+1,k, which makes P (D˜J+1,0 < D˜J+1,k) under this method
non-informative for evaluating TLGS candidates. Table 2 also presents the average probability for
comparing two candidates, P (D˜J+1,k < D˜J+1,l), where D˜J+1,l is the estimate based on a TLGS
with a true D̂J+1,l = 0, from using T
true
2,j as the estimated treatment effect on the candidate GS.
The estimates of P (D˜J+1,l < D˜J+1,k) being larger than 1/2 in almost every case suggests that this
probability can be used to discern between candidate general surrogates of differing quality.
Tables S.2 and S.3 in the supplementary materials summarize the simulations using subject level
data (as opposed to trial level summaries directly) to compare the two different ways of formulating
the within-trial likelihoods. We find that the methods are basically comparable, with the working
independence version of the likelihood having lower bias in the estimation of D̂J+1,k by D˜J+1,k,
although the bivariate normal likelihood method tends to have slightly smaller D˜J+1,k on average.
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4 Generalizability
We have outlined a method for evaluating and comparing candidate TLGS. Now we attempt to
quantify the generalizability of a TLGS to a new setting. Suppose we have a new setting (J +
1), where only the treatment effect on the TLGS is estimated. We can use our posited method
to evaluate and compare candidate TLGS in the J completed trials, then estimate the clinical
treatment effect in this new setting. However, why should we assume that this estimate is valid
in this new setting? If this new setting is similar enough to the J settings where the TLGS was
evaluated, we would have more confidence that the relationship between the TLGS and the clinical
outcome will persist in this new setting.
Information to support generalizability can be based on the characteristics of the new setting,
such as the ethnic origin and age range of the trial subjects, relative to the evaluation settings. If
information on the J evaluation settings and the new setting (J+1) is available to assess whether the
new setting’s and evaluation settings’ characteristics are similar, it will strengthen generalizability.
The characteristics that vary over the evaluation trial settings are often referred to as the units
of variation. Although this is often pointed out in meta-analytic papers, the implications of this
variation are typically not explored or discussed.
Here, we suggest guidelines for conveying the information available to support the assumption
of generalizability. In particular, we propose three ordered classes of generalizability support:
represented, within range and outside the range. If the new trial setting is exactly the same as the
evaluation setting in terms of available characteristics, findings are strongly generalizable. When
all the characteristics of a new trial are present in at least one of the observed trials, but not all
in the same one, we call the support of the generalizability assumption represented. When not
all characteristics of a new setting are represented in an observed trial, but all the characteristics
are within the range of the observed trials, we call the support for the generalizability assumption
within range. An example of this third type of support is a new trial with participants between the
ages 50 to 60 years, when previous trials enrolled 40-50 year old and 60-75 years old subjects. On
the other hand, if a new setting only enrolled 20-30 year old participants, we would call the support
for the generalizability assumption outside range. Clearly the evidence to support generalization
would be expected to decline from represented to within range to outside range.
The reliability of the above classifications hinges on observing a large number of (the same) char-
acteristics in the evaluation settings and the new study. If there are very few observed characteristics
in any of the J evaluation settings or the new setting, the information to support generalizability is
limited. The proposed nomenclature is solely a suggestion for succinctly conveying the information
available to support the assumption of generalizability.
5 Application: Pentavalent Rotavirus Vaccine
More than 450,000 children under five years died from complications of rotavirus infection each year
[Tate et al., 2012] prior to vaccine availability. The pentavalent rotavirus vaccine RotaTeqTM(RV5)
developed by Merck has been licensed for use in over 120 countries. The rotavirus Efficacy and
Safety Trial (REST) against severe rotavirus gastroenteritis [Vesikari et al., 2006] was conducted
in 11 countries. In the substudy of REST in Finland and the United States estimated efficacy was
as high as 98%. However, in other regions in Africa and Asia, lower efficacy has been observed
[Armah et al., 2010, Zaman et al., 2010]. Lower efficacy may be related to difference in participants’
immune system function. And if this is the case, such measurements could be used to better predict
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Table 3: Data available for each trial used in the analysis in Section 5.
Region/ Number of Subjects with
Protocol Number Grouping Country Clinical Outcome IgA G1
015 Asia Bangladesh 1116 146 146
005† Finland Finland 1027 644 647
006 Finland Finland 2324 358 1503
007 Finland Finland 637 54 54
015 Africa Ghana 1971 143 143
015 Africa Kenya 1137 128 128
015 Africa Mali 1667 137 137
006 Native lands United States 583 207 207
006 US concomitant United States 1239 106 104
006 US non-concomitant United States 366 220 210
007 United States United States 478 97 98
015 Asia Vietnam 871 149 149
006 Asia Taiwan 0 99 99
† Only the placebo and low, middle, and high dose RV5 groups were included.
efficacy in future settings.
We investigate several candidate trial level general surrogates using data from four phase II
and III studies of RV5 conducted in seven countries: Finland, the United States, Vietnam, Mali,
Bangladesh, Ghana and Kenya [Vesikari et al., 2006, Heaton et al., 2005, Armah et al., 2010, 2012,
Zaman et al., 2010, Shin et al., 2012]. Participants from Finland and the United States were included
in more than one study. Some of the trials involved more than one country. For the purpose of
this analysis, we assume participants from different countries in the same trial to be independent
trials as it is unlikely that outcomes will be correlated between countries even within the same trial
setting. Table 3 shows the 12 trials (based on study and country) used as our evaluation trials,
and a 13th trial in Taiwan where only the potential TLGSs are measured. The data were provided
by Merck & Co. Inc., Kenilworth, New Jersey, through data sharing agreements with the Fred
Hutchinson Cancer Research Center and the National Institute of Allergy and Infectious Diseases.
For this application we consider rotavirus gastroenteritis of any severity as the outcome of
interest. Dose, endemic burden of disease, age range, ethnicity, and region were available for each
trial. Several candidate TLGS were measured in a subset of individuals. These included serum
anti-rotavirus IgA B-cell responses (IgA), as well as serum neutralization antibody (SNA) to the
human rotavirus serotypes G1, G2, G3, G4 and P1A.
Given that the different trials collected all the markers on only a random sample of those with the
clinical outcome, we did not use the method of Dai and Hughes [2012], but instead present results
using the working-independence model (3) based on estimates obtained from fitting independent
generalized linear models in each trial for the available immunogenicity and clinical outcome data.
Figure 2 displays the point estimates and 95% credible intervals (CI) for the vaccine effect on the
clinical outcome (rate of gastroenteritis of any severity), T2,j and the vaccine effect on two selected
immune markers, SNA G1 and serum anti-rotavirus IgA, T1,j,k. Due to the limited number of trial
settings, we limited the number of candidates for comparison to the two candidates that seemed
to have the best association with outcome as seen in Figure 2. Figure S1 in the supplementary
materials describes this same relationship for all the other biomarkers collected. The smooth curve
overlaid in all figures is the posterior mean from the regression model given in (5).
13
l
l
l
l
l l
l l
l
l
l
l
0 1 2 3 4 5
−
4
−
3
−
2
−
1
0
1
G1
Estimate T1 and 95% CI
Es
tim
at
e 
T2
 a
nd
 9
5%
 C
I
l
l
l
l
l l
ll
l
l
l
l
0 2 4 6 8 10
−
4
−
3
−
2
−
1
0
1
IGA
Estimate T1 and 95% CI
Es
tim
at
e 
T2
 a
nd
 9
5%
 C
I
Figure 2: Association of Estimated Vaccine Effects. Each sub-figure displays the relationship
between the estimated treatment effect on the candidate trial level GS, T̂1,k,j , on the x-axis, and
the estimated treatment effect on the clinical outcome, T̂2,j , on the y-axis, over the 12 trial
settings. The two candidates of interest are G1 or IgA. The crossbars depict the 95% CI for the
estimates. The smooth curve overlaid is the posterior mean from the spline model given in (5).
The T2,j estimates and standard errors are obtained by fitting Poisson regression models, in-
cluding an offset for the log of follow-up time. This is the same model used in the clinical papers
on these trials [Heaton et al., 2005, Vesikari et al., 2006, Armah et al., 2010, 2012, Zaman et al.,
2010, Shin et al., 2012]. The clinical outcome in each trial is the difference in log rates of rotavirus
gastroenteritis of any severity between the vaccinated and unvaccinated. A linear model was used
to estimate the vaccine effect on the two potential TLGS with the effect being the difference in the
log titer level between the vaccinated and unvaccinated participants.
For ease of notation let k = {IgA,G1}. The mean of the predictive error distribution, DJ+1,G1 is
0.29 with a 95th percentile of 0.8; for DJ+1,IgA, 0.36, with a 95th percentile of 1.03. We find evidence
that both serum anti-rotavirus IgA and SNA G1 have value as trial level general surrogates for
rotavirus gastroenteritis of any severity in settings where they are generalizable. This can be seen in
Figure 3 and from the probabilities P (D˜J+1,0 < D˜J+1,G1) = 0.19 and P (D˜J+1,0 < D˜J+1,IgA) = 0.22
being less than 0.5. The probability P (D˜J+1,GI < D˜J+1,IgA) = 0.46 suggests the two candidates
are similar in quality. These results can also be seen in Figure 3, as both D˜J+1,IgA and D˜J+1,G1
have more mass closer to 0 and less spread than D˜J+1,0; there is also weak evidence that G1 is a
slightly better TLGS than IgA as indicated by the probability P (D˜J+1,GI < D˜J+1,IgA) = 0.46 and
by the higher peak of the D˜J+1,G1 density that is close to 0.
Only selected sites had the clinical outcome measure collected in the REST clinical trial [Vesikari
et al., 2006]. Immune measurements alone were taken at the Taiwan site. We estimate the true
clinical vaccine effect at the Taiwan site, T2,Taiwan (‘Taiwan’ corresponds to J + 1) to be -1.51
based on the vaccine effect on G1 with 95% CI (−2.3,−0.90); this corresponds to a vaccine efficacy
estimate of 78% with 95% CI (59%, 90%) against rotavirus gastroenteritis of any severity. Given the
95th percentile of the distribution D˜J+1,G1 and the the upper 95% CI limit of the credible interval
for T2,Taiwan it is unlikely there would not have been positive efficacy in Taiwan as (−0.9+0.8) < 0.
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Figure 3: Density estimates for D˜J+1,IgA, D˜J+1,G1 and D˜J+1,0
Figure S2 of the supplementary materials illustrates this graphically.
The generalizability of SNA G1 as a TLGS to Taiwan can be classified between within range
and outside of range; this trial was at the same dose, age range, burden of disease in the population,
and general region, Asia, as previous trials. However, previous trials conducted in Asia were in
Vietnam and Bangladesh, which are socioeconomically different from Taiwan.
6 Discussion
We have provided a definition of a TLGS and outlined a flexible Bayesian framework for the pre-
diction of clinical treatment effects in a new setting, given the estimated treatment effect on a
candidate TLGS. We also proposed a useful summary for the evaluation and comparison of candi-
date TLGS. We demonstrate that our prediction method generally has better predictive properties
than previous methods, particularly when the true relationship between the treatment effects is
non-linear. We also describe a nomenclature for conveying the evidence to support generalizability
of a trial level general surrogate.
In the application, we find evidence of two useful trial level general surrogates for rotavirus
gastroenteritis of any severity in the RV5 vaccine trials; similar findings suggesting serum anti-
rotavirus IgA as a surrogate have been presented by Goveia [2014]. We used the treatment effect
on SNA G1 to predict the clinical efficacy of RV5 against rotavirus gastroenteritis of any severity in
the Taiwan region and found that it is likely that there would have been positive efficacy observed
in this region if the clinical endpoint had been collected. As is demonstrated in the application
and pointed out in Section 2.1.1, our proposed method allowed us to use all available outcome and
immunogenicity data in each trial to estimate the treatment effect on the clinical outcome and
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the treatment effect on the candidate GS. Unlike other methods, subjects need not have both the
candidate trial level general surrogate and clinical outcome data in each trial, provided the implicit
missingness is not informative, as was the case in the RV5 trials.
The evaluation and comparison methods we have developed can be used with any flexible
modeling method as is demonstrated by the DH simulation results. Our proposed Bayesian non-
parametric model could also be used for the full-data model estimation, and other models could be
considered for the leave-the-jth-trial-out predictions, such as the DH model. Useful extensions to
our proposed method would be the simultaneous evaluation of the individual level GS and TLGS,
such as is discussed in Alonso et al. [2015] or the evaluation of surrogate consistency, as discussed
and demonstrated for a specific meta-analytic setting in Elliott et al. [2015]. The consideration of
combinations of measures as surrogates is also of interest for future research.
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